Maze Therapeutics (MAZE) director begins reporting with zero shares disclosed
Rhea-AI Filing Summary
Maze Therapeutics, Inc. (MAZE) reported an initial statement of beneficial ownership for Paula A. Johnson, who is identified as a director. The filing lists no reportable transactions and no derivative positions, and the summary data shows no recorded share purchases, sales, or exercises at this time.
Positive
- None.
Negative
- None.
Key Figures
Buy transactions: 0
Sell transactions: 0
Derivative transactions: 0
+2 more
5 metrics
Buy transactions
0
Number of buy transactions reported in the Form 3 transaction summary
Sell transactions
0
Number of sell transactions reported in the Form 3 transaction summary
Derivative transactions
0
Derivative transaction count in the Form 3 transaction summary
Holding entries
0
Reported holding entries for non-derivative or derivative securities
Net buy/sell direction
neutral
Overall net buy/sell direction from the transaction summary
Key Terms
Form 3, beneficial ownership, reporting person
3 terms
Form 3 regulatory
"It represents Paula A. Johnson’s initial status as a reporting person"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"reported an initial statement of beneficial ownership for Paula A. Johnson"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
reporting person regulatory
"initial status as a reporting person for Maze Therapeutics"
FAQ
What does the Form 3 filing for MAZE by Paula A. Johnson represent?
It represents Paula A. Johnson’s initial status as a reporting person for Maze Therapeutics, Inc. as a director. The filing establishes disclosure obligations going forward but currently reports no transactions or derivative positions.
Are there any derivative securities reported for Paula A. Johnson in MAZE’s Form 3?
No. The filing’s derivative section is empty and the transaction summary reports 0 derivative transactions. This means no options, warrants, or other derivative positions are disclosed in this Form 3.
Is Paula A. Johnson reported as a 10% owner of MAZE in this Form 3?
No. The reporting-person data indicates she is a director and not a 10% owner. Her role triggers reporting requirements, but the form does not categorize her as holding 10% or more of MAZE’s stock.
Does the MAZE Form 3 mention any Rule 10b5-1 trading plan for Paula A. Johnson?
No. The document-level indicator for Rule 10b5-1 status is null, and there are no transaction footnotes describing a trading plan. With no transactions reported, there is no plan-related timing information here.
AI-generated analysis. How Rhea-AI works. Not financial advice.
